Rapport CDO sells 10,115 shares under plan trade

Rapport Therapeutics, Inc. Chief Development Officer Yeleswaram Krishnaswamy sold 10,115 shares of common stock in an open-market transaction at a weighted average price of $29.9906 per share.

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. Chief Development Officer Yeleswaram Krishnaswamy sold 10,115 shares of common stock in an open-market transaction at a weighted average price of $29.9906 per share. The shares were sold in multiple trades between $29.90 and $30.18.

After this sale, Krishnaswamy directly holds 286,876 shares of Rapport Therapeutics common stock. The transaction was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating the sale was scheduled in advance.

Insider Trade Summary 10b5-1

Net Seller: 10,115 shares

Net Sell 1 txn

Insider Yeleswaram Krishnaswamy

Role Chief Development Officer

Sold 10,115 shs ($303K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,115	$29.9906	$303K

Holdings After Transaction: Common Stock — 286,876 shares (Direct)

Footnotes (2)

1. F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.90 to $30.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Rapport Therapeutics (RAPP) report for Yeleswaram Krishnaswamy?

Rapport Therapeutics reported that Chief Development Officer Yeleswaram Krishnaswamy sold 10,115 shares of common stock. The sale was an open-market transaction executed under a Rule 10b5-1 trading plan adopted on December 10, 2025, providing pre-scheduled liquidity.

At what prices did the Rapport Therapeutics (RAPP) CDO sell shares?

The reported weighted average sale price was $29.9906 per share. Individual trades occurred in multiple transactions at prices ranging from $29.90 to $30.18, and detailed breakdowns are available on request from the issuer or the SEC staff.

How many Rapport Therapeutics (RAPP) shares does the CDO hold after the sale?

Following the reported transaction, Chief Development Officer Yeleswaram Krishnaswamy directly holds 286,876 shares of Rapport Therapeutics common stock. This figure reflects his position after selling 10,115 shares in the open market under a Rule 10b5-1 trading plan.

Was the Rapport Therapeutics (RAPP) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. Such plans pre-schedule trades, which can make transaction timing less indicative of the insider’s short-term market outlook.

What does the weighted average price mean in the Rapport Therapeutics (RAPP) Form 4?

The weighted average price of $29.9906 reflects multiple individual trades between $29.90 and $30.18. The insider undertook to provide detailed per-price share amounts to the issuer, any security holder, or SEC staff upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/26/2026 - 04:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yeleswaram Krishnaswamy

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/25/2026		S(1)		10,115	D	$29.9906(2)	286,876	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.90 to $30.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

	/s/ Troy Ignelzi, Attorney-in-Fact	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)